catechin has been researched along with Aberrant Tissue in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, M; Kuboki, Y; Sato, Y; Takita, H | 1 |
| Hara, Y; Hasegawa, J; Isemura, M; Kishimoto, Y; Kohri, T; Miura, N; Ohishi, T; Shiota, G | 1 |
2 other study(ies) available for catechin and Aberrant Tissue
| Article | Year |
|---|---|
Inhibition of BMP-induced ectopic bone formation by an antiangiogenic agent (epigallocatechin 3-gallate).
Topics: Alkaline Phosphatase; Angiogenesis Inhibitors; Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Calcium; Cartilage; Catechin; Choristoma; Collagen Type II; Drug Delivery Systems; Humans; Male; Osteogenesis; Rats; Rats, Wistar; Skin Diseases; Transforming Growth Factor beta | 2002 |
Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azoxymethane; Carcinogens; Catechin; Choristoma; Colon; Colonic Neoplasms; Drug Synergism; In Situ Nick-End Labeling; Incidence; Male; Nucleolus Organizer Region; Precancerous Conditions; Rats; Rats, Inbred F344; Sulindac; Tea | 2002 |